Paola Roa

Also affiliated with Sylvester Comprehensive Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents”.

Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents

British Journal of Cancer(2024)10.1038/s41416-024-02760-1

N/A

0DataRank · unranked

13 citations

Valentina Foglizzo, Guilherme Harada, Matteo Repetto, Amanda Kulick, Elisa de Stanchina +17 more

Responsiveness of different MET tumour alterations to type I and type II MET inhibitors

Clinical and Translational Medicine(2025)10.1002/ctm2.70338

N/A

0DataRank · unranked

3 citations

Valentina Foglizzo, Jason Chang, Natasha Rekhtman, Ann Elizabeth Sisk, Jamie Gibson +20 more

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

Molecular Oncology(2025)10.1002/1878-0261.70155

N/A

0DataRank · unranked

0 citations

Lily L. Remsing Rix, Bin Fang, Eric A. Welsh, Nicole V. Bremer, Valentina Foglizzo +9 more